Key result
Noninvasive electrocardiographic tools, specifically the signal-averaged electrocardiogram and T-wave alternans, are reviewed for their mechanisms and clinical utility in sudden cardiac death risk stratification.
SAECG and TWA are FDA-approved noninvasive electrocardiographic tools used clinically for identifying patients at risk for sudden cardiac death.
Answers are grounded in this paper and cite their sources.
FDA-approved tools aid SCD risk stratification in practice; leaves open need for contemporary outcome validation.
Sudden cardiac death (SCD) is one of the leading causes of mortality in developing countries. To prevent SCD, it is crucial to have effective tools for identifying patients at risk, given that there are now effective devices and medications that can prevent SCD. Two noninvasive electrocardiographic tools have been approved by the Food and Drug Administration and are being used clinically for identifying patients at risk for SCD: the signal-averaged electrocardiogram (SAECG) and T-wave alternans (TWA). This article reviews each of these approaches and includes a discussion of the mechanisms and a summary of the clinical studies published to date.
No takes yet. Share an insight, caveat, or question.
Kunavarapu et al. (2004) conducted a review in Sudden cardiac death risk. Signal-averaged electrocardiogram (SAECG) and T-wave alternans (TWA) was evaluated. Noninvasive electrocardiographic tools, specifically the signal-averaged electrocardiogram and T-wave alternans, are reviewed for their mechanisms and clinical utility in sudden cardiac death risk stratification.
Synapse has enriched 10 related papers. Consider them for comparative context: